Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Strategy analysis > KOL Insight

KOL Insight


  • Sort by Custom
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Click to order products descending
  • Display 45 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • Follicular Lymphoma KOL Interview

    Follicular Lymphoma KOL Interview – UK

    $599.00

    This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for follicular lymphoma. Disease stratification by staging and expression as well as unmet needs are also discussed. Key assets highlighted include Rituxan, Revlimid, Gazyva, Yescarta, Imbruvica, Kymriah, Tazverik, and mosunetuzumab.

    June 11, 2021
    Find out more
  • Follicular Lymphoma KOL Interview

    $599.00

    “When people need therapy (for advanced stage Follicular Lymphoma), there’s a whole gamut. If they have relatively low volume disease, one option, which unfortunately in the community I would say is underutilized, is single-agent rituximab.”

    February 3, 2016
    Find out more
  • Epilepsy KOL Interview – US, West

    $599.00

    A US key opinion leader (KOL) discusses the epilepsy treatment landscape, including new market entrant Epidiolex, and provides their perspective on late-phase pipeline anti-epileptic drugs such as Fintepla.

    February 18, 2019
    Find out more
  • ECLIPSE Psoriasis Pulse Survey

    $599.00

    This 11-question pulse survey of 74 dermatologists practicing throughout the US and Europe asks respondents their thoughts on results from the ECLIPSE study

    January 31, 2019
    Find out more
  • Ebola KOL Interview #3

    $599.00

    Ebola KOL Interview #3

    December 2, 2014
    Find out more
  • Ebola KOL Interview #1

    $599.00

    So the history in Africa has been very extensive since the 1970s and outbreaks in those countries havehappened sporadically over the last 40 years. Here in US, right, this is our first case of anyone being sick with Ebola, and there are a number of people who have actually come into the country.

    November 2, 2014
    Find out more
  • Dyslipidemia KOL Insight Interview #2

    $599.00

    Discusses percent not meeting goal and projected usage of PCSK9 and CETP inhibitors in various scenarios based on outcomes data.

    July 28, 2014
    Find out more
  • Dyslipidemia KOL Insight Interview #1

    $599.00

    Discusses usage of PCSK9 and CETP inhibitors in various scenarios based on outcomes data

    July 25, 2014
    Find out more
  • dysliidemia-kol

    Dyslipidemia and Diabetes Reimbursement KOL Interview:

    $599.00

    Topics: Dyslipidemia and Diabetes Reimbursement PCSK9 Inhibitors, SGLT2/DPP4 Inhibitor FDCs, and Biosimilar Insulin

    August 5, 2015
    Find out more
  • Drug Pricing and Market Access KOL Interview

    $599.00

    Expensive oncology treatments [PD-1 and upcoming CAR-T therapies] will continue to be covered by large insurers formularies, but access will be restricted according to NCCN guidelines.

    February 1, 2016
    Find out more
  • : Diffuse Large B-Cell Lymphoma (DLBCL)

    Diffuse Large B-Cell Lymphoma (DLBCL) KOL Interview – US

    $599.00

    A US-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for DLBCL. Therapies discussed include Polivy, Monjuvi, Zynlonta, CD19-directed CAR-T therapy and CD20-directed bispecific antibodies.

    April 21, 2022
    Find out more
  • : Diffuse Large B-Cell Lymphoma (DLBCL)

    Diffuse Large B-Cell Lymphoma (DLBCL) KOL Interview – UK

    $599.00

    A UK-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for DLBCL. Therapies discussed include Polivy, Monjuvi, Zynlonta, CD19-directed CAR-T therapy, and CD20-directed bispecific antibodies.

    April 21, 2022
    Find out more
  • Dermatology KOL Interview

    $599.00

    BioMedTracker – Dermatology KOL Interview                                                                                                                           In recent years, patients have become more comfortable with aesthetic dermatology procedures as they have become more widespread.

    October 31, 2014
    Find out more
  • Depression KOL Interview – US #2

    $599.00

    A US expert in the depression field dives into the treatment algorithm, critical unmet needs, and pipeline drugs such as SAGE-217 and AXS-05.

    March 2, 2021
    Find out more
  • Depression KOL Interview – US #1

    $599.00

    A US expert in the depression field dives into the treatment algorithm, critical unmet needs, and pipeline drugs such as SAGE-217 and AXS-05.

    March 2, 2021
    Find out more
  • Datapack – Pharmaprojects Pharma R&D Annual Review 2017

    Datapack – Pharmaprojects Pharma R&D Annual Review 2017

    $1,999.00

    This datapack presents the supporting data behind the seminal white paper, Pharma R&D Annual Review 2017. The white paper is available for free for Biomedtracker subscribers.

    April 18, 2017
    Find out more
  • Datamonitor Schizophrenia KOL Interview 2

    $599.00

    KOL believes that the available schizophrenia treatments that provide the most efficacy also have the highest side effects.

    February 24, 2016
    Find out more
  • Datamonitor Schizophrenia KOL Interview

    $599.00

    On key factors effecting treatment: “First of all tolerability, because if the tolerability is not good then there will be no adherence. The second is efficacy, and the third one maybe is also whether the compound is also available as a depot. I think that is a major advantage if a drug, if an antipsychotic, is indeed available as a depot or as a long-acting injection (LAI).”

    February 10, 2016
    Find out more
  • Datamonitor Meningococcal Vaccines KOL Interview

    $599.00

    Datamonitor interviewed an infectious diseases specialist based in the US Greater Washington DC area to determine this physician’s views on marketed and pipeline meningococcal vaccines.

    July 12, 2016
    Find out more
  • Datamonitor Healthcare Ulcerative Colitis KOL Interviews

    $599.00

    Datamonitor Healthcare interviewed two ulcerative colitis (UC) experts, one based in Italy and the other in the US, to gauge their views on approved and late-stage pipeline drugs, treatment challenges and unmet needs and the future treatment of UC.

    August 18, 2017
    Find out more
  • Datamonitor Healthcare Type 2 Diabetes KOL Interview – US

    $599.00

    In this discussion with a US KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.

    October 12, 2018
    Find out more
  • Datamonitor Healthcare Type 2 Diabetes KOL Interview – UK

    $599.00

    In this discussion with a UK KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.

    October 12, 2018
    Find out more
  • Datamonitor Healthcare Type 2 Diabetes KOL Interview – Italy

    $599.00

    In this interview with an Italian KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.

    October 12, 2018
    Find out more
  • Datamonitor Healthcare Systemic Lupus Erythematosus KOL Interviews

    $599.00

    Datamonitor Healthcare interviewed two experts on systemic lupus erythematosus (SLE) based in the US to gauge their views on currently available treatment options, pipeline drugs and challenges with clinical trial design in SLE.

    August 18, 2017
    Find out more
  • Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interview – US

    $599.00

    An interview with a US key opinion leader (KOL) on seasonal influenza vaccination coverage rates and trends in main risk groups, key marketed vaccines, pipeline approaches, and the potential for a universal influenza vaccine

    November 19, 2018
    Find out more
  • Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interview – UK

    $599.00

    An interview with a UK key opinion leader (KOL) on seasonal influenza vaccination coverage rates and trends in main risk groups, key marketed vaccines, pipeline approaches, and the potential for a universal influenza vaccine.

    November 19, 2018
    Find out more
  • Datamonitor Healthcare Non-Small Cell Lung Cancer KOL Interview – NY, US

    $1,099.00

    Datamonitor Healthcare interviewed a US-based oncologist with clinical trial and commercial experience of PD-1/L1 inhibitors to gauge his views

    August 30, 2018
    Find out more
  • Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Reimbursement

    $599.00

    This reimbursement interview with a US key opinion leader (KOL) provides insight into pricing strategies, pricing barriers, and potential reimbursement criteria for non-alcoholic steatohepatitis therapies.

    May 20, 2019
    Find out more
  • Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US

    $599.00

    This interview with a US key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies, diagnostic tools, and future treatment rates for the different fibrosis stages of NASH. Key pipeline assets highlighted include Ocaliva, elafibranor, cenicriviroc, and firsocostat.

    May 20, 2019
    Find out more
  • Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – France

    $599.00

    This interview with a French key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies and future treatment rates for the different fibrosis stages of NASH.

    May 20, 2019
    Find out more
  • Datamonitor Healthcare Multiple Myeloma KOL Interview – UK

    $599.00

    This interview covers the current treatment of multiple myeloma in the UK, and the main areas of unmet need.

    January 18, 2019
    Find out more
  • Datamonitor Healthcare Multiple Myeloma KOL Interview – Midwestern, US

    $599.00

    This interview covers the current treatment of multiple myeloma in the US, and the main areas of unmet need.

    January 18, 2019
    Find out more
  • Datamonitor Healthcare Meningococcal and Pneumococcal Vaccines KOL Interview – US

    $599.00

    An interview with a US key opinion leader (KOL) on meningococcal and pneumococcal vaccination coverage rates, vaccination rate trends in main risk groups, key marketed vaccines, pipeline approaches, and addressing unmet needs.

    November 9, 2018
    Find out more
  • Datamonitor Healthcare Meningococcal and Pneumococcal Vaccines KOL Interview – UK

    $599.00

    An interview with a UK key opinion leader (KOL) on meningococcal and pneumococcal vaccination coverage rates, vaccination rate trends in main risk groups, key marketed vaccines, pipeline approaches, and addressing unmet needs.

    November 12, 2018
    Find out more
  • Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #2

    $599.00

    A US key opinion leader (KOL) discusses the approach to treating major depressive disorder as well as the most pressing unmet needs in the market, and provides insights into key late-phase pipeline drugs for major depressive disorder.

    October 2, 2018
    Find out more
  • Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #1

    $599.00

    A US key opinion leader (KOL) discusses key late-phase pipeline and marketed drugs for major depressive disorder and highlights the significance of unique mechanisms of action in the market.

    October 2, 2018
    Find out more
  • Datamonitor Healthcare Infectious Diseases Disease Analysis: Seasonal Influenza Vaccines

    $599.00

    The seasonal influenza vaccines market in the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK) is expected to continue to expand over the next 10 years, largely due to the continued uptake of premium-priced vaccines in the elderly subgroup, including quadrivalent forms of Fluzone High-Dose (HD) and Fluad, as well as the launch of the first-in-class adjuvanted nanoparticle vaccine, NanoFlu.

    October 30, 2020
    Find out more
  • Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – US, West Coast

    $599.00

    A US key opinion leader (KOL) provides insight into the current and future treatment dynamics of HR+/HER2- breast cancer, as well as critical unmet needs in the treatment space.

    January 8, 2019
    Find out more
  • Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – US, Midwest

    $599.00

    A US key opinion leader (KOL) provides insight into the current and future treatment dynamics of HR+/HER2- breast cancer, as well as critical unmet needs in the treatment space.

    January 8, 2019
    Find out more
  • Datamonitor Healthcare HR+/HER2- Breast Cancer KOL Interview – UK

    $599.00

    A UK key opinion leader (KOL) provides insight into the current and future treatment dynamics of HR+/HER2- breast cancer, as well as critical unmet needs in the treatment space.

    January 8, 2019
    Find out more
  • Datamonitor Healthcare HIV KOL Interview – US #2

    $599.00

    A US key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

    January 25, 2019
    Find out more
  • Datamonitor Healthcare HIV KOL Interview – US #1

    $599.00

    A US key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

    January 25, 2019
    Find out more
  • Datamonitor Healthcare HIV KOL Interview – UK

    $599.00

    A UK key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

    January 25, 2019
    Find out more
  • Datamonitor Healthcare HIV KOL Interview – Germany

    $599.00

    A German key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

    January 25, 2019
    Find out more
  • Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – US, South #2

    $599.00

    This interview provides a thorough description of hepatocellular carcinoma (HCC) treatment in the US. All targeted therapies available for HCC treatment are discussed, as well as a discussion of Phase III pipeline drugs and the potential impact these therapies would have if they gain approval.

    February 6, 2019
    Find out more
Page 3 of 5
Page 3 of 512345
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London, SW1P 1WG. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top